Dispositivos en falla cardíaca

Autores/as

  • Juan Manuel Sénior Universidad de Antioquia. Hospital Universitario San Vicente Fundación https://orcid.org/0000-0001-8312-7194
  • Nelson Darío Giraldo Ramírez Hospital Pablo Tobón Uribe

DOI:

https://doi.org/10.17533/udea.iatreia.26744

Palabras clave:

falla cardíaca, guía, marcapasos artificial

Resumen

Introducción: la implantación de un marcapasos para estimulación eléctrica cardíaca con tres electrodos, conocido comúnmente como resincronizador, se ha convertido en una terapia útil en algunos pacientes con síndrome de falla cardíaca. Estudios observacionales sugieren que hasta 30 % de las muertes en pacientes con cardiomiopatía dilatada son por muerte cardíaca súbita; el cardiodesfibrilador implantable (CDI) ha surgido como respuesta innovadora a esta problemática en pacientes seleccionados con alto riesgo de muerte cardíaca súbita

Metodología: para la creación de la guía de práctica clínica (GPC) basada en la evidencia se siguieron los pasos definidos en la Guía Metodológica para la Elaboración de Guías de Práctica Clínica con Evaluación Económica en el Sistema General de Seguridad Social en Salud Colombiano del Ministerio de Salud y Protección Social.

Resultados: se establecen las recomendaciones de implantación de dispositivos en pacientes con falla cardíaca.

Conclusión: los ensayos clínicos con asignación aleatoria han demostrado consistentemente que la terapia de resincronización y el cardiodesfibrilador reducen la mortalidad en pacientes con falla cardíaca con disminución de la fracción de eyección en ciertos escenarios.

|Resumen
= 139 veces | PDF
= 48 veces|

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Juan Manuel Sénior, Universidad de Antioquia. Hospital Universitario San Vicente Fundación

Coordinador del posgrado en Cardiología Clínica y Cardiología Intervencionista, Universidad de Antioquia. Cardiólogo intervencionista, Hospital Universitario San Vicente Fundación, Medellín, Colombia.

Nelson Darío Giraldo Ramírez, Hospital Pablo Tobón Uribe

Médico intensivista, Hospital Pablo Tobón Uribe, Medellín, Colombia.

Citas

(1.) Rodelo J, Rendon J, Sénior J. Dispositivos de estimulacion electrica en falla cardíaca. En: Sindrome de falla cardíaca y trasplante, Sénior J, Editor. Bogotá: Distribuna; 2011. p. 225-36.

(2.) Grines CL, Bashore TM, Boudoulas H, Olson S, Shafer P, Wooley CF. Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony. Circulation. 1989;79(4):845-53.

(3.) Aleksova A, Carriere C, Zecchin M, Barbati G, Vitrella G, Di Lenarda A, et al. New-onset left bundle branch block independently predicts long-term mortality in patients with idiopathic dilated cardiomyopathy: data from the Trieste Heart Muscle Disease Registry. Europace. 2014;16(10):1450-9.

(4.) Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53(11):976-81.

(5.) Van Bommel RJ, Bax JJ, Abraham WT, Chung ES, Pires LA, Tavazzi L, et al. Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis. Eur Heart J. 2009;30(20):2470-7.

(6.) Chen Y, Duan C, Liu F, Shen S, Chen P, Bin J. Impact of etiology on the outcomes in heart failure patients treated with cardiac resynchronization therapy: a meta-analysis. PLoS One. 2014;9(4):e94614.

(7.) Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J. 2006;27(22):2682-8.

(8.) Gomez F, Astudillo Ramirez BV, Orrego CM. Terapia de resincronizacion con implante de electrodo ventricular izquierdo por via epicardica.Rev Col Cardiol 2007; 14: 284-290.

(9.) Carrasquilla G, Pulido A, De la Hoz A, Mieth K, Muñoz O, Guerrero R et al. Guía Metodológica para la elaboración de guías de práctica clínica con evaluación económica en el Sistema General de Seguridad Social en Salud Colombiano. Segunda edición, Versión completa final. Bogotá, 2014 [actualizado marzo 2014; última consulta Noviembre 2015]. Disponible en: http://gpc.minsalud.gov.co/recursos/Documents/Gu%C3%ADa%20Metodológica_Web.pdf

(10.) Daubert JC, Saxon L, Adamson PB, Auricchio A, Berger RD, Beshai JF, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 2012;14(9):1236-86.

(11.) Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15(8):1070-118.

(12.) Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2013;61(12):1318-68.

(13.) Exner DV, Birnie DH, Moe G, T guidelines on the use of cardiac resynchronization therapy: evidence and patient selection. Can J Cardiol. 2013;29(2):182-95.

(14.) Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J. 2010;31(21):2677-87.

(15.) Stevenson WG, Hernandez AF, Carson PE, Fang JC, Katz SD, Spertus JA, et al. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail. 2012;18(2):94-106.

(16.) Abraham WT, Young JB, León AR, Adler S, Bank AJ, Hall SA, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110(18):2864-8.

(17.) Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52(23):1834-43.

(18.) Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385-95.

(19.) Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329-38.

(20.) Santangeli P, Di Biase L, Pelargonio G, Dello Russo A, Casella M, Bartoletti S, et al. Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2011;32(2):125-35.

(21.) Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014;370(18):1694-701.

(22.) Van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol. 2011;58(10):995-1000.

(23.) Kraai IH, Vermeulen KM, Luttik ML, Hoekstra T, Jaarsma T, Hillege HL. Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Fail. 2013;15(10):1113-21.

(24.) Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite biventricular pacing in patients wit heart failure and intraventricular conductions delay. N Engl J Med 2001; 344: 873-80.

(25.) Abraham W, Fisher W, Smith A et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-53.

(26.) Young J, Abraham WT, Smith A et al. Combined cardiac resynchronization and implantable cardioversión defibrillation in advanced chronic heart failure. JAMA 2003; 289:2685-2694.

(27.) Bristow M, Saxon L, Boehmer J et al. Cardiac resyn chronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-50.

(28.) Cleland JF, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality. N Engl J Med 2005; 352:1539-49.

(29.) Higgins SL, Hummel JD, Niazi IK et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42: 1454-9.

(30.) McAlister F, Ezekowitz J, Hooton N et al. Cardiac resynchronization therapya for patients with left ventricular dysfunction. A systematic Review. JAMA 2007;297:2502-2514.

(31.) Stavrakis S, Lazzara R, Thadani U. The benefit of cardiac resynchronization therapy and QRS duration: a metaanalysis. J Cardiovasc Electrophysiol 2012; 23:163-168.

(32.) Sipahi I, Carrigan T, Rowland D, Stambler B, Fang J. Impact of QRS duration on clinical event reduction with cardíaca resynchronization therapy. Arc Intern Med 2011; 171:1454-1462.

(33.) Jiang M, Zhang Q. Comparison of CRT and CRT-D in heart failure: systematic review of controlled trials. Int J Cardiol 2012;158:39-45.

(34.) Auricchio A, Stellbrink C, Sack S, et al. Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol. 2002;39:2026-2033.

(35.) Auricchio A, Stellbrink C, Butter C, et al; Pacing Therapies in Congestive Heart Failure II Study Group; Guidant Heart Failure Research Group. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol. 2003;42:2109-2116.

(36.) Leclerq C, Cazeau S, Lellouche D et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: The RD-CHF stydy. Pacing Clin Electrophysiol 2007;30 suppl 1: 23-30.

(37.) Kindermann M, Hennen B, Jung J, Geisel J, Bohm M, Frohlig G. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE). J Am Coll Cardiol. 2006;47:1927-1937.

(38.) US Food and Drug Administration. St Jude Medical Frontier model 5508L and Frontier II model 5586 Cardiac Resynchronization Therapy Pacemakers (CRT-P) supported on the model 3510 programmer platforms with the model 3307, v4.8m programmer software, VecTOR 2005. Acceso 5 de abril 2015. http://www.accessdata.fda.gov/cdrh_docs/pdf3/P030035S003b.pdf.

(39.) Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119(18):2516-25.

(40.) Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920-5.

(41.) Kamath GS, Steinberg JS. Cardiac resynchronization therapy and atrial fibrillation. Cardiol J. 2009;16(1):4-10.

(42.) Hayes DL, Boehmer JP, Day JD, Gilliam FR, Heidenreich PA, Seth M, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8(9):1469-75.

(43.) Colchero T, Arias MA, López-Sánchez FA, Pachón M, Domínguez-Pérez L, Puchol A, et al. Loss of continuous biventricular pacing in cardiac resynchronization therapy patients: incidence, causes, and outcomes. Rev Esp Cardiol (Engl Ed). 2013;66(5):377-83.

(44.) Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol. 2009;53(4):355-60.

(45.) Kamath GS, Cotiga D, Koneru JN, Arshad A, Pierce W, Aziz EF, et al. The utility of 12-lead Holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. J Am Coll Cardiol. 2009;53(12):1050-5.

(46.) Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2011;8(7):1088-94.

(47.) Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011;32(19):2420-9.

(48.) Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ, et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2012;5(5):566-70.

(49.) Mazza A, Bendini MG, Leggio M, Riva U, Ciardiello C, Valsecchi S, et al. Incidence and predictors of heart failure hospitalization and death in permanent pacemaker patients: a single-centre experience over medium-term follow-up. Europace. 2013;15(9):1267-72.

(50.) Burns KV, Kaufman CL, Kelly AS, Parah JS, Dengel DR, Bank AJ. Torsion and dyssynchrony differences between chronically paced and non-paced heart failure patients. J Card Fail. 2011;17(6):495-502.

(51.) De Sisti A, Márquez MF, Tonet J, Bonny A, Frank R, Hidden-Lucet F. Adverse effects of long-term right ventricular apical pacing and identification of patients at risk of atrial fibrillation and heart failure. Pacing Clin Electrophysiol. 2012;35(8):1035-43.

(52.) Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med. 2000;342(19):1385-91.

(53.) Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002;346(24):1854-62.

(54.) Eberhardt F, Bode F, Bonnemeier H, Boguschewski F, Schlei M, Peters W, et al. Long term complications in single and dual chamber pacing are influenced by surgical experience and patient morbidity. Heart. 2005;91(4):500-6.

(55.) Yu CM, Chan JY, Zhang Q, Omar R, Yip GW, Hussin A, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med. 2009;361(22):2123-34.

(56.) Ritter O, Koller ML, Fey B, Seidel B, Krein A, Langenfeld H, et al. Progression of heart failure in right univentricular pacing compared to biventricular pacing. Int J Cardiol. 2006;110(3):359-65.

(57.) Albertsen AE, Nielsen JC, Poulsen SH, Mortensen PT, Pedersen AK, Hansen PS, et al. Biventricular pacing preserves left ventricular performance in patients with high-grade atrio-ventricular block: a randomized comparison with DDD(R) pacing in 50 consecutive patients. Europace. 2008;10(3):314-20.

(58.) Martinelli Filho M, de Siqueira SF, Costa R, Greco OT, Moreira LF, D’avila A, et al. Conventional versus biventricular pacing in heart failure and bradyarrhythmia: the COMBAT study. J Card Fail. 2010;16(4):293-

(59.) Albertsen AE, Mortensen PT, Jensen HK, Poulsen SH, Egeblad H, Nielsen JC. Adverse effect of right ventricular pacing prevented by biventricular pacing during long-term follow-up: a randomized comparison. Eur J Echocardiogr. 2011;12(10):767-72.

(60.) Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368(17):1585-93.

(61.) Lemoine S, Sadoul N, Blangy H, Baumann C, Brembillat-Perrot B, Selton-Suty C, et al. Effects of ventricular resynchronization in previously paced patients developing refractory heart failure. Arch Cardiovasc Dis. 2008;101(10):605-9.

(62.) Yannopoulos D, Lurie KG, Sakaguchi S, Milstein S, Ermis C, VanHeel L, et al. Reduced atrial tachyarrhythmia susceptibility after upgrade of conventional implanted pulse generator to cardiac resynchronization therapy in patients with heart failure. J Am Coll Cardiol. 2007;50(13):1246-51.

(63.) Eldadah ZA, Rosen B, Hay I, Edvardsen T, Jayam V, Dickfeld T, et al. The benefit of upgrading chronically right ventricle-paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. Heart Rhythm. 2006;3(4):435-42.

(64.) Höijer CJ, Meurling C, Brandt J. Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure: a double-blind, randomized crossover study. Europace. 2006;8(1):51-5.

(65.) Wokhlu A, Rea RF, Asirvatham SJ, Webster T, Brooke K, Hodge DO, et al. Upgrade and de novo cardiac resynchronization therapy: impact of paced or intrinsic QRS morphology on outcomes and survival. Heart Rhythm. 2009;6(10):1439-47.

(66.) Sweeney MO, Prinzen FW. A new paradigm for physiologic ventricular pacing. J Am Coll Cardiol. 2006;47:282– 8.

(67.) Steinberg JS, Fischer A, Wang P, et al. The clinical implications of cumulative right ventricular pacing in the Multicenter Automatic Defibrillator Trial II. J Cardiovasc Electrophysiol. 2005;16:359–65.

(68.) Prinzen FW, Vernooy K, Auricchio A. Cardiac resynchronization therapy: state-of-the-art of current applications, guidelines, ongoing trials, and areas of controversy. Circulation. 2013;128(22):2407-18.

(69.) Parkash R, Philippon F, Shanks M, Thibault B, Cox J, Low A, et al. Canadian Cardiovascular Society guidelines on the use of cardiac resynchronization therapy: implementation. Can J Cardiol. 2013;29(11):1346-60.

(70.) Nery PB, Ha AC, Keren A, Birnie DH. Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block: a systematic review. Heart Rhythm. 2011;8(7):1083-7.

(71.) Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J. 2012;163(2):260-7.e3.

(72.) Birnie DH, Ha A, Higginson L, Sidhu K, Green M, Philippon F, et al. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2013;6(6):1190-8.

(73.) Kang SH, Oh IY, Kang DY, Cha MJ, Cho Y, Choi EK, et al. Cardiac resynchronization therapy and QRS duration: systematic review, meta-analysis, and metaregression. J Korean Med Sci. 2015;30(1):24-33.

(74.) Leong DP, Höke U, Delgado V, Auger D, Thijssen J, van Erven L, et al. Predictors of long-term benefit of cardiac resynchronization therapy in patients with right bundle branch block. Eur Heart J. 2012;33(15):1934-41.

(75.) Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34(46):3547-56.

(77.) Risum N. Assessment of mechanical dyssynchrony in cardiac resynchronization therapy. Dan Med J. 2014;61(12):B4981.

(78.) Tanaka H, Nesser HJ, Buck T, Oyenuga O, Jánosi RA, Winter S, et al. Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study. Eur Heart J. 2010;31(14):1690-700.

(79.) Yancy CW, McMurray JJ. ECG--still the best for selecting patients for CRT. N Engl J Med. 2013;369(15):1463-4.

(80.) Van Rees JB, de Bie MK, Thijssen J, Borleffs CJW, Schalij MJ, van Erven L. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol. 2011;58(10):995-1000.

(81.) Singh JP, Klein HU, Huang DT, Reek S, Kuniss M, Quesada A, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation. 2011;123(11):1159-66.

(82.) Wilton SB, Exner DV, Healey JS, Birnie D, Arnold MO, Sapp JL, et al. Left ventricular lead position and outcomes in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Can J Cardiol. 2014;30(4):413-9.

(83.) Kusumoto FM, Calkins H, Boehmer J, Buxton AE, Chung MK, Gold MR, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation 2014; 130(1):94-125.

(84.) Wijers SC, van der Kolk BYM, Tuinenburg a E, Doevendans P a F, Vos M a, Meine M. Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: Which patients do benefit? Neth Heart J. 2013;21(6):274–83.

(85.) Bansch D. Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT). Circulation. 2002;105(12):1453–8.

(86.) Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia AMIOVIRT. J Am Coll Cardiol. 2003;41(10):1707–12.

(87.) Kadish A, Dyer A, Daubert JP, Quigg R, Estes N a M, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.

(88.) Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352(3):225–37.

(89.) McAnulty J, Halperin B. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.

(90.) Kuck K-H, Cappato R, Siebels J, Ruppel R. Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Cardiac Arrest : The Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102(7):748–54.

(91.) Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian Implantable Defibrillator Study (CIDS) : A Randomized Trial of the Implantable Cardioverter Defibrillator Against Amiodarone. Circulation. 2000;101(11):1297–302.

(92.) Desai A, Fang J, Maisel WH, Baughman KL. Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy. A Meta-analysis of Randomized Controlled Trials. JAMA. 2004;292(23):2874–9.

(93.) Hernandez AF, Fonarow GC, Hammill BG, Al-Khatib SM, Yancy CW, O’Connor CM, et al. Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. Circ Heart Fail. 2010;3(1):7–13.

(94.) Borne RT, Varosy PD, Masoudi F a. Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches. JAMA Intern Med. 2013;173(10):859–65.

(95.) Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable Cardioverter Defibrillator in High-Risk Long QT Syndrome Patients. J Cardiovasc Electrophysiol. 2003;14:337–41.

(96.) McAnulty J, Halperin B. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.

(97.) Connolly S, Hallstrom A. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21:2071–8.

(98.) Siebels J, Kuck K, Investigators C. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994;127(1139):1139–44.

(99.) Wever EF, Hauer RN, van Capelle FL, Tijssen JG, Crijns HJ, Algra A, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995;91(8):2195–203.

(100.) García-Pérez L, Pinilla-Domínguez P, García-Quintana A, Caballero-Dorta E, García-García FJ, Linertová R, et al. Economic evaluations of implantable cardioverter defibrillators: a systematic review. Eur J Health Econ. 2015; 16(8):879-93.

(101.) Moss A, Hall W. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335(26):1933–40.

(102.) Buxton A, Lee K, Fisher J, Josephson M, Prystowsky E, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882–90.

(103.) Moss A, Zareba W, Hall W. Prophylactic Implantation Of A Defibrillator In Patients With Myocardial Infarction And Reduced Ejection Fraction. N Engl J Med. 2002;346(12):877–83.

(104.) Ezekowitz J. Implantable Cardioverter Defibrillators in Primary and Secondary Prevention : A Systematic Review of Randomized , Controlled Trials. Ann Intern Med. 2003;138:445–53.

(105.) Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol. 2004;44(11):2166–72.

(106.) Theuns D a MJ, Smith T, Hunink MGM, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace. 2010;12(11):1564–70.

(107.) Bigger J, Investigators Cpt. Prophylactic Use Of Implanted Cardiac Defibrillators In Patients At High Risk For Ventricular Arrhythmias After Coronary-Artery Bypass Graft Surgery. N Engl J Med. 1997;337(22):1569–75.

(108.) Hohnloser S, Kuck K. Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction. N Engl J Med. 2004;352(24):2481–8.

(109.) Steinbeck G, Andresen D. Defibrillator Implantation Early after Myocardial Infarction. N Engl J Med. 2009;361(15):1427–36.

(110.) Peck KY, Lim YZ, Hopper I, Krum H. Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients. Int J Cardiol. 2014;173(2):197–203.

(111.) Noyes K, Corona E, Zwanziger J, Hall WJ, Zhao H, Wang H, et al. Health-Related Quality of Life Consequences of Implantable Results From MADIT II. Med Care. 2007;45(5):377–85.

(112.) Mark D, Anstrom K. Quality of Life with Defibrillator Therapy or Amiodarone in Heart Failure. N Engl J Med. 2008;359(10):999–1008.

Descargas

Publicado

07-02-2017

Cómo citar

1.
Sénior JM, Giraldo Ramírez ND. Dispositivos en falla cardíaca. Iatreia [Internet]. 7 de febrero de 2017 [citado 13 de noviembre de 2024];29(4-S):S160-188. Disponible en: https://revistas.udea.edu.co/index.php/iatreia/article/view/26744

Número

Sección

Suplemento

Artículos más leídos del mismo autor/a

<< < 1 2